JP Morgan Chase
PRME icon

JP Morgan Chase’s Prime Medicine PRME Stock Holding History

JP Morgan Chase’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.66M Buy
844,154
+408,444
+94% +$1.55M ﹤0.01% 3890
2025
Q4 		$1.51M Buy
435,710
+392,321
+904% +$1.75M ﹤0.01% 4316
2025
Q3 		$240K Buy
43,389
+10,354
+31% +$42.1K ﹤0.01% 5423
2025
Q2 		$81.6K Sell
33,035
-2,628
-7% -$4.05K ﹤0.01% 5696
2025
Q1 		$71K Buy
35,663
+23
+0.1% +$59 ﹤0.01% 5737
2024
Q4 		$104K Sell
35,640
-1,742
-5% -$6.12K ﹤0.01% 5745
2024
Q3 		$145K Sell
37,382
-805
-2% -$3.73K ﹤0.01% 5545
2024
Q2 		$196K Sell
38,187
-3,894
-9% -$23.6K ﹤0.01% 5173
2024
Q1 		$295K Sell
42,081
-3,438
-8% -$26.1K ﹤0.01% 5108
2023
Q4 		$403K Buy
45,519
+18,505
+69% +$143K ﹤0.01% 4930
2023
Q3 		$258K Sell
27,014
-3,658
-12% -$47.5K ﹤0.01% 4905
2023
Q2 		$449K Buy
30,672
+17,775
+138% +$248K ﹤0.01% 4554
2023
Q1 		$159K Buy
12,897
+3,023
+31% +$49.2K ﹤0.01% 5194
2022
Q4 		$184K Buy
+9,874
New +$178K ﹤0.01% 5079

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

JP Morgan Chase's PRME Position: Q1 2026 in Review

JP Morgan Chase increased its Prime Medicine (PRME) stake by 94% in Q1 2026, buying an estimated $1.55M and bringing the position to 844,154 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #3890.

JP Morgan Chase first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • JP Morgan Chase held 844,154 shares of Prime Medicine worth $2.66M as of Q1 2026.
  • JP Morgan Chase bought 408,444 Prime Medicine shares in Q1 2026, an estimated $1.55M.
  • Prime Medicine made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3890 holding.
  • JP Morgan Chase first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.